m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05058
 [1]
Non-coding RNA LINC00266-1 IGF2BP1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification MYC MYC IGF2BP1 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
m6A Target Myc proto-oncogene protein (MYC)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Septin 14 pseudogene 20 (SEPTIN14P20/LINC00266-1) LncRNA View Details
Regulated Target Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary LINC00266-1 binds to IGF2BP1 and strengthens m6A recognition by IGF2BP1 on RNAs, such as Myc proto-oncogene protein (MYC) mRNA, to increase the mRNA stability and expression of c-Myc, thereby promoting tumorigenesis.
Pathway Response RNA degradation hsa03018
Cell Process RNA stability
In-vitro Model
 SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
HeLa Endocervical adenocarcinoma Homo sapiens CVCL_0030
HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model NOD-SCID mice in each experimental group were injected with 2 × 106 HCT-116-Luc-LINC00266-1-ORF-Flag, HCT-116-Luc-LINC00266-1-5'U, or HCT-116-Luc-LINC00266-1-MT cells through the tail vein (n = 5). The metastatic foci were visualized 9 weeks after implantation using an IVIS 200 Imaging System (Xenogen).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Myc proto-oncogene protein (MYC) 3 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name AVI-5126 Phase 2 [2]
Synonyms
Resten-CP; NeuGene (CABG), AVI
    Click to Show/Hide
External Link
TTD: D01VDI
 Compound Name Resten-NG Phase 2 [3]
Synonyms
Resten-NG (TN)
    Click to Show/Hide
External Link
TTD: D0M4MG
 Compound Name TWS-119 Investigative [4]
Synonyms
TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
    Click to Show/Hide
External Link
CID: 9549289
TTD: D0T8KR
References
Ref 1 An oncopeptide regulates m(6)A recognition by the m(6)A reader IGF2BP1 and tumorigenesis. Nat Commun. 2020 Apr 3;11(1):1685. doi: 10.1038/s41467-020-15403-9.
Ref 2 Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. doi: 10.1089/jop.2011.0135. Epub 2011 Dec 7.
Ref 3 Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 4 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.